NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout

    India
    Business
    World
    Politics
    Sports
    Technology
    Entertainment
    Auto
    Lifestyle
    Inspirational
    Career
    Bengaluru
    Delhi
    Mumbai

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
    Home / News / India News / COVAXIN is 200% safe: Bharat Biotech MD on efficacy concerns
    Next Article
    COVAXIN is 200% safe: Bharat Biotech MD on efficacy concerns

    COVAXIN is 200% safe: Bharat Biotech MD on efficacy concerns

    By Siddhant Pandey
    Jan 04, 2021
    10:54 pm

    What's the story

    Bharat Biotech MS Krishna Ella on Monday said the company has "tremendous experience" in developing vaccines and their vaccine, COVAXIN, is "200% safe."

    The statement comes amid backlash over emergency approval for the restricted use of the vaccine, which was granted on Sunday.

    Some experts and the Opposition have questioned the regulatory approval in the absence of efficacy data from Phase III trials.

    Vaccine

    COVAXIN Phase III trials still underway

    COVAXIN is an inactivated vaccine, i.e., it uses an inactivated or killed pathogen (SARS-CoV-2) to trigger an immune response.

    It has been developed jointly by Bharat Biotech and the Indian Council of Medical Research's National Institute of Virology (ICMR-NIV).

    Phase III trials of the vaccine are yet to be completed, however, at least 22,500 out of 25,800 intended subjects have been vaccinated.

    Quote

    'Merck's Ebola vaccine received emergency approval without trial'

    Addressing a presser, Ella said, "Merck's Ebola vaccine never completed a human clinical trial at all but WHO gave emergency authorization for Liberia and Guinea."

    He said, "Now that the vaccine is being politicized, I want to state very clearly that none of my family members is associated with any political party. Many people are just gossiping. It's just a backlash against Indian companies."

    Experience

    'Not a company without experience; we don't deserve this'

    Ella said the company does not deserve the backlash as they have submitted sufficient data that is available on the internet.

    "We are not a company without experience in vaccines," he said, "We are touching 123 countries. We are the only company that has got such extensive experience and extensive publication in review journals."

    COVAXIN trials were conducted in over 12 countries, he added.

    Quote

    'People should have patience to read our articles'

    Ella further said, "Many people say that I am not transparent in my data. I think people should have the patience to read on the internet and how many articles we have published. More than 70 articles have been published in various international journals."

    Safety

    COVAXIN showed less than 10% adverse reactions, says Ella

    Ella said, "COVAXIN has shown less than 10% adverse reactions, while others have 60-70% adverse reactions. AstraZeneca was giving 4g paracetamol to volunteers to suppress such reactions. We haven't given paracetamol to any volunteer."

    "I can assure you our vaccine is 200% safe," he said.

    Ella also requested a week's time for confirmed data on the vaccine's efficacy against the new strain of coronavirus.

    New strain

    COVAXIN will work better against new strain, says government

    A new strain of SARS-CoV-2 has caused a stir as authorities say it can be as much as "70% more infectious."

    India has reported at least 52 such cases so far.

    Health Minister Dr. Harsh Vardhan and ICMR Director-General Dr. Balram Bhargava have said that COVAXIN has a better chance against the new strain as it uses a killed version of the whole virus.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Latest
    Ministry of Health and Family Welfare
    Bharat Biotech
    AstraZeneca
    COVAXIN

    Latest

    Sikh businessman shot dead in Canada; assailants fired 15-16 roundsĀ  Canada
    SA delay WTC preparations, IPL franchises breathe sigh of relief BCCI
    Tom Cruise's 'Mission: Impossible' gets 5-minute standing ovation at Cannes Cannes Film Festival
    Guneet Monga debuts 'Women in Film India' fellowship at Cannes Cannes Film Festival

    Ministry of Health and Family Welfare

    Government approves use of dexamethasone for moderate, severe COVID-19 cases Union Health Ministry
    CPL 2020 to begin on August 18 behind closed doors Cricket: News, Stats and more!
    UP government to implement 'mini' lockdown every weekend Uttar Pradesh
    US: Squirrel tests positive for Bubonic plague World Health Organization

    Bharat Biotech

    ICMR, Bharat Biotech teaming up to develop Indian COVID-19 vaccine Indian Council of Medical Research (ICMR)
    India's first COVID-19 vaccine, COVAXIN, cleared for human trials Coronavirus
    India targets to launch first COVID-19 vaccine by August 15 Indian Council of Medical Research (ICMR)
    India's second COVID-19 vaccine cleared for human trials: Details here Drugs Controller General of India

    AstraZeneca

    COVID-19 vaccine: What are the latest updates? Oxford
    #GoodNews: Oxford's COVID-19 vaccine may be available by September-end Oxford
    As coronavirus pandemic surges, some vaccine makers expect to profit Pfizer
    Meet Adar Poonawalla, the man bringing COVID-19 vaccines to India Oxford University

    COVAXIN

    Coronavirus, that killed over 500,000, isn't even nearing end: WHO South Korea
    Following globally-accepted norms, says ICMR over August 15 vaccine target Vaccine
    Expert panel sets conditions, ICMR's COVAXIN August-15 target looks unachievable Indian Council of Medical Research (ICMR)
    India's COVID-19 vaccines: What are the latest updates? Vaccine
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2025